CARDIOASPIRIN 100 mg Compresse gastroresistenti

DRUG2 trials

Sponsors

Fondazione IRCCS Istituto Nazionale Dei Tumori, Fondazione Toscana Gabriele Monasterio

Conditions

Patients with atrial fibrillation undergoing percutaneous left atrial appendage closure with the Amulet deviceSubjects at high risk of inflammatory state and mortality from lung cancerother cancers and all causes

Phase 2

A randomized trial of multi-factorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program

Not yet recruitingCTIS2024-513660-26-00

Fondazione IRCCS Istituto Nazionale Dei Tumoriother cancers and all causes, Subjects at high risk of inflammatory state and mortality from lung cancer

Target: 2000Updated: 2024-08-05

Phase 4

Head-to-head compaRison of single versus dual antiplatelet treatMent strategY after percutaneous left atrial appenDage closure: A MULticenter, randomizEd sTudy. The ARMYDA-AMULET study

RecruitingCTIS2024-515361-34-00

Fondazione Toscana Gabriele MonasterioPatients with atrial fibrillation undergoing percutaneous left atrial appendage closure with the Amulet device

Start: 2021-10-13Target: 606Updated: 2025-12-19